Resources
Did you mean
compound annual growth rate (4 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Air-Handling With Care
- Advances in pharmaceutical research and development have allowed increasingly selective compounds to be synthesized, better targeting disease with minimal side effects. Often, therapeutic doses are on the order of micrograms. And this increased specificity means that the compounds have increased potency. This article points out that the increasingly potent compounds...
- White papers
- Insulin: Beyond the Injection?
- With the number of diabetes patients steadily rising, the race to replace conventional needles for insulin delivery becomes all the more important, and lucrative. Clear leaders are emerging, but there have been few real successes and many documented failures. The Holy Grail is some kind of easy oral dosage, and...
- White papers
- Synthesis of Commercial Phosphodiesterase(V) Inhibitors
- The literature syntheses including patents of three commercial phosphodiesterase V (PDE5) inhibitors (sildenafil, vardenafil, and tadalafil) are reviewed with particular emphasis on largescale manufacture. For each of these compounds, some impressive chemical development work has been reported. Further uses of these compounds are being proposed and investigated in the paper.
- White papers 2005-01-06
- Enrichment of Ligands for the Serotonin Receptor Using the Shape Signatures Approach
- Shape Signatures, a new 3-dimensional molecular comparison method, has been adapted to rank ligands of the serotonin receptors. A set of 825 agonists and 400 antagonists together with approximately 10 000 randomly chosen compounds from the NCI database were used in this study. Both 1D and 2D Shape Signature databases...
- White papers 2004-12-02
- Improving the Pharma Research Pipeline
- Drug compounds that pharmaceutical company's license from third-party developers cost less, are more successful in clinical trials, and achieve commercial results no worse than those of internally generated compounds. As pharma companies struggle to keep their drying pipelines full, they should take a look at what makes licensed compounds so...
- White papers 2004-08-01
- A Guide to Lead Exposure in the Construction Industry
- Lead is a cumulative and toxic substance. People who swallow or inhale lead compounds may become ill or die from lead poisoning. Employers must be aware of workplace hazards facing their workers and must take appropriate action to minimize or eliminate exposure to these hazards. This paper discusses precautions that...
- White papers 2003-06-11
- Drug Delivery Outsourcing
- From the executive summary: ‘There are many different reasons for pharmaceutical and biotechnology companies to look to drug delivery technology providers as partners in the drug development process. Drug delivery systems clearly differentiate a drug in today’s highly competitive pharmaceutical marketplace, or salvage promising compounds that have been shelved due...
- White papers 2003-01-01
- Development of a Laccase-Based Flow Injection Electrochemical Biosensor for the Determination of Phenolic compounds and Its Application for Monitoring Remediation
- This paper describes the development of a new system for amperometric determination of phenolic compounds, and its application for monitoring these compounds in paper mill effluent. The method was based on a flow system, a dialysis sampler, and a laccase-based biosensor. The performance of this system was investigated with respect...
- White papers 2002-01-07
Additional Resources
- SciClone Reports Results for the First Quarter 2008
- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the first quarter ended March 31, 2008. "Over the course of the first quarter, product revenues from ZADAXIN®sales increased 23% to exceed $10 million, and for the first time, we areproviding quarterly financial data for SciClone China to quantify the valueof...
- Articles 2008-05-08
- CDEX Announces the Addition of Heparin Signatures to ValiMed(TM) to Address Medication Errors and Contamination
- CDEX Inc. (OTCBB: CEXI) announces that it nowhas seven heparin Signatures in its ValiMedTM Signature Libraryencompassing a range of concentrations and diluents, including typicalneonatal and pediatric doses. (A signature is an electronic fingerprint ofa medication at a given concentration in a prescribed diluent.) ValiMed isused both to train...
- Articles 2008-05-08
- Cohesive Cold Seal Film features biodegradable design
- Available in clear, tinted, and co-ex film types, Biodegradable Cohesive Film creates secure, weather-resistant and tamper-evident packages. Product if formulated to biodegrade in months when buried or discarded in landfills, breaking down into mineral and organic compounds and leaving no toxic residue. Supplied in rolls from 3-80 in. wide and...
- Articles 2008-05-07
- Cleveland BioLabs Completes Recruitment for Phase II Hormone-Refractory Prostate Cancer Trial
- Cleveland BioLabs, Inc. (NASDAQ: CBLI),announced today that it has fully enrolled its Phase II clinical trial ofCuraxin CBLC102 in advanced, hormone-refractory androgen independentprostate cancer. This open label trial is evaluating the safety and efficacy of CuraxinCBLC102 for use in treating patients with hormone-refractory metastaticprostate cancer. Curaxins have multiple mechanisms...
- Articles 2008-05-07
- Focus Financial Partners Names Financial Services Leaders Deborah Doyle McWhinney and William I. Campbell to Its Board of Directors
- NEW YORK -- Focus Financial Partners, LLC, the largest partnership of independent wealth management firms, today announced that Deborah ("Debby") Doyle McWhinney and William ("Bill") I. Campbell have been appointed to its Board of Directors. "We are thrilled to have Bill and Debby join us as active Board...
- Articles 2008-05-07
- Osteologix IND for NB S101 for Osteoporosis Accepted by FDA
- SAN FRANCISCO -- Osteologix, Inc. (OLGX.OB), a specialty biopharmaceutical company, today announced that the U. S. Food and Drug Administration FDA has accepted its Investigational New Drug IND application for its lead development candidate NB S101 strontium malonate, for the treatment and prevention of osteoporosis. NB S101, a dual acting...
- Articles 2008-05-07
- Acucela Files Investigational New Drug Application
- ---- Orally-available Small Molecule for Dry Form of AMD ---- BOTHELL, Wash. -- Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has filed an investigational new drug IND application to conduct a Phase 1 clinical trial for its...
- Articles 2008-05-07
- JER Secures First Purchase Order for Exclusive Material for Sprig Toys
- JER Envirotech International Corp. (TSX-V: JER) (FRANKFURT: KFTB) ("JER") is pleased to announce that the firstpurchase order for wood polymer compounds has been received from SprigToys, Inc. ("Sprig") of Fort Collins, Colorado. Sprig is a developer of environmentally friendly, "kid-powered" electronicvehicles and accessories. The company recently released its SprigAdventure...
- Articles 2008-05-07
- Koppers Holdings Inc. Board Declares Regular Dividend
- The Board of Directors of Koppers HoldingsInc. (NYSE: KOP) today declared a quarterly dividend of $0.22 per commonshare, payable July 1, 2008, to stockholders of record as of the close ofbusiness on May 19, 2008. About Koppers Koppers, with corporate headquarters and a research center in Pittsburgh,Pennsylvania, is a global...
- Articles 2008-05-07
- Bristol-Myers Squibb to Present at Healthcare Conference
- * Will Reaffirm 3-Year 15% Compound Annual Growth Rate of Earnings Per Share * Expects to Update 2008 Earnings Guidance No Later Than End of Second Quarter NEW YORK -- Bristol-Myers Squibb Company (NYSE:BMY) will present today at the 33rd Annual Deutsche Bank Healthcare Conference. Lamberto...
- Articles 2008-05-07
- Ferro's Engineered Polymer Products Business Announces Price Increases for Filled and Reinforced Plastic compounds
- CLEVELAND -- Ferro Corporation's (NYSE:FOE) Engineered Polymer Products business has announced it is increasing the price for all filled and reinforced plastic compounds produced at its facility in Evansville, IN. The increase of $0.06 per pound is effective with shipments made as of June 1, 2008, or as supply contracts...
- Articles 2008-05-07
- smartFOCUS included in Magic Quadrant for Multichannel Campaign Management, 1Q08
- - Evaluation Based on Completeness of Vision and Ability to Execute - BRISTOL, United Kingdom -- smartFOCUS Group plc (LSE: STF), a leading international multichannel marketing software company, today announced it has been positioned by Gartner, Inc. in the '1H08 Multichannel Campaign Management Magic Quadrant' report. ...
- Articles 2008-05-07
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
